Monday, April 13, 2015 10:25:31 AM
I get particularly excited about biotech companies, but I am absolutely overjoyed when they are actually conducting clinical trials. You can probably guess why; biotech companies thrive on clinical trials because the sooner they get them done, the sooner they can get FDA approval and make millions, sometimes in even billions of dollars in revenues.
The story is no different with my latest tip. CMXC comes to the market with a unique e-balance technology that helps in the therapeutic treatment of conditions such as diabetes. The company has just completed phase 1 pilot clinical trial and going by the release, it looks like CMXC is on its way to really big things.
The good news from your perspective is that CMXC is not as expensive as you’d expect – it’s not there yet, at least. This gives more time for you to capitalize.
To learn more about CMXC please visit their website: www.cellmedx.com
CMXC is trading 28 cents and has remarkable upside potential. The 12-month high is a lofty 1.15 and volatility levels are now starting to sing. In terms of timing, you have a very good entry opportunity, so don’t let it slip!
Cell MedX Corp. [OTCBB: CMXC] is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., CMXC is also engaged in the resale and marketing of spa technology and equipment.
Recent CMXC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/29/2024 06:57:28 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/06/2024 09:49:24 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/22/2024 09:38:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 05:48:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 11:08:43 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 08:29:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 08:36:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 08:27:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:02:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2023 09:20:06 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM